Second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant (SCT), based on the patient's eligibility for transplant, is the standard treatment approach for patients with relapsed or refractory disease. The management of patients
Search Results
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016
Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar, and Pierluigi Porcu
Updates in Treatment Strategies for Hodgkin Lymphoma
Ranjana H. Advani
Given the myriad of treatment options available for frontline treatment of advanced-stage Hodgkin lymphoma (HL) and for relapsed HL, clinicians must evaluate the advantages and disadvantages of each regimen, balancing risk with benefit for the
Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond
Jae Park
cell transplant (HSCT). At the NCCN 2019 Annual Congress: Hematologic Malignancies, Jae Park, MD, Associate Attending Physician, Memorial Sloan Kettering Cancer Center, summarized key studies of novel immunotherapies in relapsed/refractory (R/R) ALL and
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba
the reduction of long-term toxicity. However, 10% to 20% 3 – 6 of patients with favorable features and early-stage disease and up to 30% 7 , 8 with advanced-stage disease experience relapse. The standard treatment option for chemosensitive patients
Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Presented by: Jennifer R. Brown
—typically obinutuzumab in the frontline setting and rituximab in the relapsed setting,” Dr. Brown noted at the NCCN 2021 Virtual Congress: Hematologic Malignancies. “But we still, nonetheless, have many unanswered questions.” According to Dr. Brown, current efforts in
BIO23-022: Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center’s Tobacco Treatment Offerings: An Acceptability Pilot Study
Riley Walton Jackson, Ann Cao-Nasalga, Amy Chieng, Amy Pirkl, Annemarie D. Jagielo, Cindy Tran, Emilio Goldenhersch, Nicolas Rosencovich, Cristian Waitman, and Judith J. Prochaska
50% or more, and two quit for 24-hours then relapsed; 3 (33%) reported some dizziness with app use; 7 of 9 (77%) would recommend MindCotine to a friend. Conclusions: In an acceptability pilot study of a novel VR-MET tobacco treatment app offered to
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma
Anthony J. Olszanski
Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair
Multiple Myeloma, Version 1.2013
Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Cristina Gasparetto, Francisco Hernandez-Illizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Michael Liedtke, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Furhan Yunus, Dorothy A. Shead, and Rashmi Kumar
responsible for MM has led to the development of novel agents. The availability of many novel evidence-based options for the treatment of MM has led to significant improvements in response and survival. Most patients with MM experience relapse or become
Updates in the Treatment of Multiple Myeloma
Presented by: Shaji K. Kumar
diagnosis for patients with active myeloma that needs treatment, and to incorporate risk stratification, which is critical in terms of deciding upon the overall treatment goals and approaches over time . . . . Unfortunately, patients continue to relapse. We
In Defense of Hepatic Arterial Infusion for Hepatic Metastases of Colorectal Cancer
Nancy Kemeny
infusion. Results were compared with those of 125 consecutive patients who received adjuvant folfox or folfiri after resection with a median follow-up of 43 months. Abbreviations: FUDR, floxuridine; HAI, hepatic arterial infusion; RFS, relapse
